Q1 Earnings Estimate for ONCY Issued By Zacks Research

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz forecasts that the company will earn ($0.06) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. Zacks Research also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday, March 27th. Wall Street Zen raised shares of Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Oncolytics Biotech Price Performance

ONCY stock opened at $0.91 on Thursday. The stock has a market capitalization of $105.20 million, a PE ratio of -3.12 and a beta of 0.98. The company’s 50-day moving average is $0.97 and its 200-day moving average is $1.05. Oncolytics Biotech has a 1 year low of $0.33 and a 1 year high of $1.51.

Hedge Funds Weigh In On Oncolytics Biotech

Large investors have recently added to or reduced their stakes in the business. Scientech Research LLC bought a new position in Oncolytics Biotech in the 3rd quarter valued at about $25,000. Blair William & Co. IL bought a new position in Oncolytics Biotech in the 4th quarter valued at about $28,000. Security National Bank of Sioux City Iowa IA bought a new position in Oncolytics Biotech in the 4th quarter valued at about $29,000. Ground Swell Capital LLC bought a new position in Oncolytics Biotech in the 4th quarter valued at about $30,000. Finally, CIBC Private Wealth Group LLC bought a new position in Oncolytics Biotech in the 4th quarter valued at about $44,000. Institutional investors own 6.82% of the company’s stock.

Insider Buying and Selling at Oncolytics Biotech

In other Oncolytics Biotech news, Director Patricia S. Andrews purchased 35,400 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average price of $0.86 per share, with a total value of $30,444.00. Following the transaction, the director owned 78,128 shares in the company, valued at $67,190.08. The trade was a 82.85% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernd R. Seizinger purchased 100,000 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was acquired at an average cost of $1.04 per share, for a total transaction of $104,000.00. Following the transaction, the director owned 466,991 shares in the company, valued at $485,670.64. This represents a 27.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 404,282 shares of company stock worth $363,232 in the last quarter. 0.10% of the stock is owned by insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.